Entrada Therapeutics, Inc.

NASDAQ:TRDA

Biotechnology

Healthcare
$5.03 +0.37%

+$0.03 today

Market cap
$196.93M
Beta
-0.26
P/E (TTM)
-1.7
EPS (TTM)
-$3.97
52W Low $4.93High $16.45

Volume 0.82M

Average 0.36M

TRDA Operating Cash Flow

Cash generated by the company's core business operations during the period.

Entrada Therapeutics, Inc.NASDAQ: TRDA

Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Operating cash flow grows, but more slowly than its trailing trend

Q1 FY2026 operating cash flow of $41.7M (cash outflow) rose 8.3% year over year, behind the +141.5% change in trailing-twelve-month operating cash flow. Sequentially, it rose 29.5% from the prior quarter. Over 3 fiscal years it compounded at +11.1% a year.

Context

  • Operating cash flow amounted to 505.5% of revenue in FY2025, up 485.8 pp from a year earlier.
  • Operating cash flow increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +8.3% toward the trailing-twelve-month pace of +141.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$41.7M+29.5% QoQ
Last fiscal yearDec 2025
-$128.51M+209.2% YoY
LTMMar 2026
-$131.7M+141.5% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+8.3%——
1 year+209.2%——
3-year CAGR+11.1%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(128.51M) USD
Year-over-year change
-209.2%

Operating Cash Flow vs competitors

How TRDA compares with its peers on the latest reported figures

  • TRDA's LTM Mar 2026 operating cash flow of $131.7M is the 2nd largest of the 11 companies compared; the peer median is $97.09M.
  • Its year-over-year change of +141.5% is the highest of 11, against a peer median of +8.2%.
  • Operating cash flow amounts to 2295.2% of revenue for TRDA, versus a peer median of 239.9%.
TRDA Competitors Peer median
Operating Cash Flow for TRDA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$147.86M +17.2%+3.0%—
TRDAEntrada Therapeutics, Inc.LTM Mar 2026$131.7M +141.5%+11.1%2295.2%
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$127.99M +14.3%+119.6%350.7%
VNDAVanda Pharmaceuticals Inc.LTM Mar 2026$126.51M +124.0%—58.1%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$109.23M -44.6%-12.2%—
HUMAHumacyte, Inc.LTM Mar 2026$101.54M +2.2%+13.9%5037.0%
CAPRCapricor Therapeutics, Inc.LTM Mar 2026$92.63M +105.1%——
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$58.57M -34.4%—129.2%
IMRXImmuneering CorporationLTM Mar 2026$49.7M -7.3%+0.9%—
ACHVAchieve Life Sciences, Inc.LTM Mar 2026$45.31M +27.4%+9.6%—
SGMTSagimet Biosciences Inc.LTM Mar 2026$39.73M -21.7%+23.1%—
Peer median (excluding TRDA) $97.09M+8.2%+9.6%239.9%

Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(51.16M)(94.62M)(6.69M)65.63M(143.75M)
Depreciation & Amortization1.12M1.9M2.84M3.77M4.1M
Deferred Income Tax00000
Stock-Based Compensation2.53M9.9M13.11M17.92M19.61M
Change in Working Capital(3.42M)(11.11M)136.32M(118.85M)(4.8M)
Accounts Receivables0002.2M2.5M
Inventory00000
Accounts Payables(715K)5.29M(2.81M)991K(1.8M)
Other Working Capital(2.71M)(16.4M)139.12M(122.04M)(5.5M)
Other Non-Cash Items74K151K(5.78M)(10.02M)(3.67M)
Operating Cash Flow(50.86M)(93.79M)139.8M(41.56M)(128.51M)
Capital Expenditures(4.58M)(2.89M)(5.61M)(3.16M)(1.04M)
Acquisitions (Net)00000
Purchases of Investments0(221.98M)(407.21M)(437.72M)(141.61M)
Sales of Investments076.21M274.43M413.08M259.46M
Other Investing Activities00000
Investing Cash Flow(4.58M)(148.65M)(138.4M)(27.8M)116.81M
Debt Repayment00000
Common Stock Issued190.69M479K19.41M99.61M887K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities939K01.63M3.36M0
Financing Cash Flow307.46M479K21.04M102.96M887K
Effect of Forex Changes0(3.95M)000
Net Change in Cash252.02M(245.91M)22.45M33.61M(10.82M)
Free Cash Flow(55.44M)(96.67M)134.19M(44.72M)(129.55M)

Entrada Therapeutics, Inc.

NASDAQ:TRDA

Intrinsic Alpha fair value

Locked

Current Price

$5.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.